Britt Lisa P., Senior VP and Chief HR Officer at Thermo Fisher Scientific (TMO), has demonstrated a clear selling bias in her recent insider transactions, with $16.77 million in total sales compared to $5.01 million in purchases across 34 reported trades. Her activity has been exclusively concentrated in TMO shares, with no transactions in other companies. The most significant disposals occurred in November 2025, including a $4.84 million sale on November 7 and two separate $622,135 transactions on November 12. These were supplemented by smaller periodic sales, such as four transactions on February 28, 2026, ranging from $44,507 to $136,879. The pattern suggests an ongoing divestment strategy, with no recent purchases to offset the sales.
While some filings with $0 values likely represent equity awards or position adjustments, the monetization trend is evident. The transactions follow a structured approach, with multiple same-day sales at varying amounts, possibly tied to prearranged trading plans. The absence of any buys since at least February 2025 reinforces the directional bias toward reducing exposure to TMO stock. Given her executive role, the sales could reflect personal portfolio management rather than a market view, but the consistency and scale of disposals are notable. The most recent activity—four sales totaling over $360,000 in late February 2026—confirms the continuation of this trend.
AI-assisted summary